Articles Companion animals

18 October 2021

Adjuvant carboplatin for treatment of splenic hemangiosarcoma in dogs

Increasing postoperative peripheral monocyte counts might be associated with a poorer prognosis

Doxorubicin-based chemotherapy after splenectomy remains the standard of care for hemangiosarcoma in dogs, but prognosis is generally poor.

To determine clinical outcome with carboplatin chemotherapy after splenectomy compared to doxorubicin-based protocols. A secondary objective was to determine if peripheral monocyte count was associated with prognosis.

Medical data from 40 dogs with histopathologically confirmed stage I or II hemangiosarcoma treated with splenectomy and carboplatin (n = 18) or doxorubicin-based protocols (n = 22) were evaluated.

Retrospective study. Statistical associations were assessed using the Kaplan-Meier method for survival times and log rank analysis for differences in survival time. Demographic information and survival times were obtained via medical records. Blood monocyte counts before and after surgery were documented.

Median survival times were 160 days (48 to >559) and 139 days (54-975), for dogs in the carboplatin (n = 18) and doxorubicin (n = 22) groups respectively (P = .82, hazards ratio [HR] [95% CI] = 1.075 [0.56-2.07]). The median survival time for dogs whose monocyte counts decreased between splenectomy and chemotherapy initiation was 265 days, compared to 66 days for dogs with increased monocytes (P = .002, HR [95% CI] = 4.17 [1.21-14.39]).

Carboplatin could be considered as an alternative in cases where doxorubicin might be contraindicated. Increasing postoperative peripheral monocyte counts might be associated with a poorer prognosis.

“Adjuvant carboplatin for treatment of splenic hemangiosarcoma in dogs: Retrospective evaluation of 18 cases (2011-2016) and comparison with doxorubicin-based chemotherapy”.

Erica A Faulhaber, et al. J Vet Intern Med. 2021 Jul;35(4):1929-1934. doi: 10.1111/jvim.16212.

Like0

Dislike0

List
Add

Please enter a comment

Name *

Email address *

Comment *

* Required fields

Information on the processing of your personal data
We inform you that, in compliance with the provisions of current national and European regulations for the Protection of Personal Data and Services of the Information Society and Electronic Commerce, by sending us this form you are expressly giving your consent to Grupo Asís Biomedia , SL, (hereinafter, "ASIS GROUP") so that, as the person in charge, it may process your personal data in order to respond to your request for contact and information by electronic means.

Likewise, when you expressly consent, we will process your personal data to send you specialized information, newsletters, offers and exclusive promotions from GRUPO ASIS and related companies.

For the aforementioned purpose, GRUPO ASIS may transfer your data to other companies linked to GRUPO ASIS or to third party service providers for the management of electronic communications and other security services, even in cases where they are outside of the European Union, provided that they legally guarantee the adequate level of protection required by European regulations.

At any time you can withdraw the consent given and exercise the rights of access, rectification, deletion, portability of your data and limitation or opposition to its treatment by contacting GRUPO ASIS by sending an email to protecciondatos @ grupoasis.com, or by written communication to address at Centro Empresarial El Trovador, 8th floor, office I, Plaza Antonio Beltrán Martínez 1, 50002, Zaragoza (Spain), indicating in either case the Ref. Personal data and the right you exercise, as well as attaching a copy of your ID or replacement identification document.

I have read and accept the treatment of my data according to the informed purpose and according Legal notes and the Privacy Policy
I wish to receive commercial information from GRUPO ASIS and related companies

Dislike0

EVENTS

Edrapublishing

About Us Authors Contact Us Legal Notes Privacy Search

Top

Adjuvant carboplatin for treatment of splenic hemangiosarcoma in dogs

Increasing postoperative peripheral monocyte counts might be associated with a poorer prognosis

Comments

List

Add

Tag

Related Articles

09 February 2022
A New Drug to Help Relieve Chemotherapy Induced Diarrhea in Dogs

A New Drug to Help Relieve Chemotherapy Induced Diarrhea in Dogs

24 January 2025
Pathological findings of mammary gland carcinoma and hemangiosarcoma cases in two African wild dogs (Lycaon pictus)

Pathological findings of mammary gland carcinoma and hemangiosarcoma cases in two African wild dogs (Lycaon pictus)

13 March 2023
Hemangiosarcoma of the nasal planum in cats

Hemangiosarcoma of the nasal planum in cats

18 December 2021
Diagnostic value of the ultrasonographic description of a splenic mass or nodule as cavitated in 106 dogs with nontraumatic hemoabdomen

Diagnostic value of the ultrasonographic description of a splenic mass or nodule as cavitated in 106 dogs with nontraumatic hemoabdomen

More news

One Committed and Caring NC State Veterinary Student, So Many Choices

Dentalis Earns 5 VOHC® Seals, Positioning for Global Expansion in Animal Health

Advancing the 3Rs: innovation, implementation, ethics and society

Automated Knowledge-Based Radiation Treatment Planning in Canine and Feline Nasal Tumors

Does Lung Function Imaging Modality Have a Dosimetric Impact On Functional Avoidance Treatment Planning: Assessment Using Prospective Clinical Trial Data

Newsletter

News of interest

Advancing the 3Rs: innovation, implementation, ethics and society

Automated Knowledge-Based Radiation Treatment Planning in Canine and Feline Nasal Tumors

One Committed and Caring NC State Veterinary Student, So Many Choices

Philanthropic Support and Specialized Surgery Saves Dog with Oral Tumor

EVENTS